TGFB1 and neoplasm: There is currently at least one ongoing clinical trial targeting TGFβ in PDAC (Table 1) that is investigating the pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR439459 alone and in combination with cemiplimab.